Projects per year
Organisation profile
Fields of science
- 302016 Gastroenterology
- 302025 Hepatology
- 302030 Internal medicine
Profiles
-
VICTRIVA: A Randomized, Double-blind, Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With lntravenous Vedolizumab and Oral Upadacitinib Compared With lntravenous Vedolizumab and Oral Placebo for lnduction Followed by lntravenous Vedolizumab Monotherapy for Maintenance in the Treatment of Adults With Moderately to Severely Active Crohn's Disease
Moschen, A. (PI), Prommer, R. (Co-PI), Klenske, E. (Researcher), Pimingstorfer, P. (Researcher), Rathenböck, M. D. (Researcher), Kainberger, M. (Administration) & Zaunmair, P. (Administration)
28.03.2025 → 27.03.2030
Project: Clinical studies › Clinical Study (Industry project)
-
Einfluss von über die Muttermilch übertragenem Lipocalin 2 auf die Etablierung und Reifung des frühkindlichen Mikrobioms und des Darmimmunsystems
Hoog, A. (Researcher) & Watschinger, C. (PI)
01.01.2022 → 31.12.2023
Project: Funded research › Other sponsors
-
Roche_NK cells in IBD
Moschen, A. (PI)
14.01.2021 → 14.01.2022
Project: Funded research › Other sponsors
-
Association of serum zinc with mineral stress in chronic kidney disease
Sohail, A., Obereigner, J., Mitter, G., Schmid, T., Hofer, A.-S., Schuster, G., Hügl, A., Dorninger, A. H., Mandl, M., Pasch, A., Lackner, H. K., Papousek, I., Dieplinger, B., Suessner, S., Antlanger, M., Cejka, D., Alesutan-Völkl, I. & Völkl, J., Sept 2024, In: Clinical Kidney Journal. 17, 9, 11 p., sfae258.Research output: Contribution to journal › Article › peer-review
Open Access -
Augmentative effects of leukemia inhibitory factor reveal a critical role for TYK2 signaling in vascular calcification
Alesutan-Völkl, I., Razazian, M., Luong, T. T. D., Estepa, M., Pitigala, L., Henze, L. A., Obereigner, J., Mitter, G., Zickler, D., Schuchardt, M., Deisl, C., Makridakis, M., Gollmann-Tepeköylü, C., Pasch, A., Cejka, D., Suessner, S., Antlanger, M., Bielesz, B., Müller, M. & Vlahou, A. & 1 others, , Oct 2024, In: Kidney International. 106, 4, p. 611-624 14 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Clopidogrel for Proteinuria Reduction in Focal Segmental Glomerulosclerosis: Phase 2 Trial Design
Daniel-Fischer, L., Antlanger, M., Cejka, D., Eller, K., Gauckler, P., Odler, B., Windpessl, M. & et al., Feb 2024, In: Kidney International Reports. 9, 2, p. 478-481 4 p.Research output: Contribution to journal › Article › peer-review
Open Access
Activities
-
GUS Advisory Board - Johnson & Johnson
Moschen, A. (Participant)
04 Dec 2025Activity: Participating in or organising an event › Participating in a conference, workshop, ...
-
TASC Meeting 2025 - Johnson & Johnson
Moschen, A. (Participant)
21 Nov 2025Activity: Participating in or organising an event › Participating in a conference, workshop, ...
-
CE&B IBD Standalone - Johnson & Johnson
Moschen, A. (Participant)
14 Nov 2025 → 15 Nov 2025Activity: Participating in or organising an event › Participating in a conference, workshop, ...